Virazole study
Executive Summary
ICN and its Viratek and SPI Pharmaceutical subsidiaries have signed a 15-year agreement with the U.S. Army Medical Research & Development Command for "cooperative study of the antiviral drug" ribavirin, according to a June 18 announcement. The Army has agreed to file "one or more NDAs for intravenous and oral" ribavirin within nine and 24 months, respectively.